BB Biotech reported a net loss of 241 million Swiss francs in Q1 2025, compared to a 260 million franc profit last year, due to volatile U.S. pharmaceutical markets and…
The biopharmaceutical industry is central to China's strategic goals, merging economic growth, public welfare, and national security. China shifts from producing generic drugs to innovating in life sciences, competing globally…
Edesa Biotech appoints Peter J. Weiler as Chief Financial Officer starting May 1, 2025, to enhance drug development efforts for immuno-inflammatory diseases. Weiler brings extensive pharmaceutical experience, previously holding key…
Edesa Biotech appoints Peter J. Weiler as Chief Financial Officer, effective May 1, 2025, marking a significant leadership change. Weiler succeeds Stephen Lemieux, who transitions to an advisory role, maintaining…
Wacker Biotech and RNAV8 Bio have embarked on a transformative mRNA technology partnership, aiming to revolutionize medicine. Wacker Biotech brings advanced microbial fermentation capabilities, enhancing pharmaceutical protein and pDNA production.…
Relay Therapeutics is undergoing significant changes with workforce reductions and cost-cutting to focus on clinical ambitions. The company has reduced its annual research budget by 75% and cut 70 jobs…
The pharmaceutical industry's R&D is driven by a competitive pursuit of innovation and breakthroughs. Merck continues its prominence in oncology and vaccines, aiming for long-term impact through strategic R&D investment.…
The pharmaceutical and biotech sectors exhibited resilience amid broad economic turmoil, largely unaffected by sweeping tariffs. Companies like Catalyst Pharmaceuticals and Veeva Systems experienced only minor stock declines, while Amgen…
ERBC and Menarini Biotech have formed a strategic alliance to revolutionize early-stage biopharmaceutical development. This partnership bridges the gap between scientific research and clinical trials through combined expertise in non-clinical…
The biotech and pharmaceutical sectors are undergoing significant layoffs, driving strategic shifts and financial recalibrations. Companies like Nkarta and ElevateBio are reducing workforces to focus on core innovations and cost-effective…